The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Lilly/ImClone; Novartis; Pfizer; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Lilly/ImClone; Pfizer; Roche/Genentech
Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).
 
Martin Reck
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Roche
 
Luis G. Paz-Ares
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Pfizer; Roche/Genentech
 
Paolo Bidoli
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly
 
Federico Cappuzzo
No Relationships to Disclose
 
Shaker R. Dakhil
No Relationships to Disclose
 
Denis Moro-Sibilot
No Relationships to Disclose
 
Hossein Borghaei
Honoraria - Bristol-Myers Squibb; Celgene
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly
Research Funding - Millennium (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly
 
Melissa Lynne Johnson
Honoraria - Genentech
Consulting or Advisory Role - Astellas Pharma (I); Otsuka (I)
Research Funding - Novartis
 
Robert M. Jotte
Honoraria - Bristol-Myers Squibb; Lilly
Speakers' Bureau - Bristol-Myers Squibb; Lilly
 
Nathan A. Pennell
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Astex Pharmaceuticals (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech (Inst); Newlink Genetics (Inst)
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Merck/Schering Plough; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Recombio; Synta
Research Funding - Boehringer Ingelheim (Inst)
 
Anne S. Tsao
Consulting or Advisory Role - Astellas Pharma; Boehringer Ingelheim; Genentech/Roche; Imedex; Lilly; MedImmune; Novartis
Research Funding - Genentech/Roche (Inst); MedImmune (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Novartis
 
Gebra Cuyun Carter
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Faye Diehl
Employment - Lilly
 
Ekaterine Alexandris
Employment - Lilly
Leadership - Lilly
Stock and Other Ownership Interests - Lilly
 
Pablo Lee
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Annamaria Zimmermann
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Joseph Treat
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Andreas Sashegyi
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Maurice Perol
Honoraria - Lilly
Consulting or Advisory Role - Lilly
Speakers' Bureau - Lilly